Praxis Precision Medicines kept mostly quiet about its research on central nervous system disorder (CNS) drugs until May, when it emerged from stealth and revealed $100 million in cumulative financing. Now the company is aiming to raise about that amount in an IPO that will fund clinical development of its drug pipeline.
Cambridge, MA-based Praxis is developing drugs intended to address the misfiring neuronal circuitry at the root of some neurological disorders. The company’s drugs are based on research into genetic mutations that regulate neuronal circuits in the brain whose dysregulation leads to the seizures in rare, inherited forms of… Read more »
UNDERWRITERS AND PARTNERS
